Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. (DTCFF) is a clinical-stage biopharmaceutical company pioneering next-generation cancer therapies and precision drug delivery systems. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic partnerships, and technological advancements.
Access the latest press releases and news covering Accum™-enabled therapeutics, including radiopharmaceuticals, antibody-drug conjugates (ADCs), and immune-oncology vaccines. Stay informed about regulatory milestones, licensing agreements, and intellectual property developments that underscore the company’s position in the biotech sector.
Key updates include progress in Phase I trials for AccuTOX®, collaborations with research institutions, and patent grants for novel drug delivery methods. All content is curated to provide a comprehensive view of Defence Therapeutics’ scientific and corporate trajectory.
Bookmark this page for streamlined access to verified updates on DTCFF’s innovations in oncology and infectious disease treatment. Regularly updated to reflect the company’s evolving role in advancing targeted therapies.
Defence Therapeutics (OTCQB:DTCFF) announced that holders of its 8% convertible debentures issued November 16, 2024, converted all principal and accrued interest into common shares upon maturity on November 16, 2025.
The principal amount of $1,476,000 converted into 2,460,000 shares at a conversion price of $0.60 per share, and $118,080 of accrued interest converted into 147,600 shares at $0.80 per share, totalling 2,607,600 shares and an aggregate amount of $1,594,080.
Defence Therapeutics (OTCQB: DTCFF) announced a strategic shift to supply its proprietary Accum drug‑delivery platform to antibody‑drug conjugate (ADC) developers after presenting at the World ADC Conference and CPHI.
Defence reported completed preclinical studies showing Accum‑conjugated Kadcyla produced ~20‑fold higher anti‑tumor efficacy than Kadcyla alone at the same 0.5 mg/kg dose in JIMT‑1 HER2+ mouse xenografts, with a near‑complete response in 90% of mice.
The company is engaging ADC partners to license or supply Accum for improving potency and reducing toxicity across ADC programs.
Defence Therapeutics (OTCQB:DTCFF) presented new preclinical data on its proprietary Accum platform at the 16th World ADC Conference in San Diego (November 4-5, 2025).
Presenters said Accum enhanced intracellular delivery and payload release in ADCs, improving potency and therapeutic index in the data shown. Defence announced plans to expand collaborative and internal testing of Accum across multiple commercial and clinical-stage ADC constructs to evaluate plug-and-play applicability across different antibodies and payloads.
The company indicated active engagement with industry partners to accelerate evaluations and explore potential benefits for targeted cancer therapies.
Defence Therapeutics (OTCQB: DTCFF) reported preclinical in vivo results for Accum-Kadcyla in HER2-positive breast cancer mouse models on November 4, 2025.
The study found ~20-fold higher anti-tumor efficacy for Accum-Kadcyla versus Kadcyla at the same dose 0.5 mg/kg, with tumor growth largely halted and a durable near-complete response in most treated mice. 100% survival and no signs of toxicity were reported during the study. Defence plans additional HER2-positive and HER2-low model testing and to advance partner discussions.
Defence Therapeutics (OTCQB: DTCFF) will present new scientific data on its Accum technology at the 16th World ADC Conference in San Diego on November 4-5, 2025.
The presentation highlights Accum's role in improving intracellular delivery and endosomal escape for antibody-drug conjugates (ADCs), aiming to enhance potency and reduce off-target toxicity. Company scientists Maxime Parisotto and Mark Lambermon will be available at the poster in the Conference Exhibition Hall, Town & Country Resort, to discuss the results and ongoing R&D.
Defence Therapeutics (OTCQB: DTCFF) will attend CPHI Worldwide 2025 in Frankfurt, Germany from October 28-30, 2025, the company stated on October 6, 2025. According to the press release, Defence plans to engage potential partners across the biopharma value chain, learn about pharmaceutical manufacturing trends, and connect with international collaborators and shareholders.
The company also invited attendees to an informal Meet & Greet on October 29, 2025 from 4:30–6:30 PM at the American May lobby bar of the Kimpton Hotel in Frankfurt and listed contact options via the CPHI partnering platform and LinkedIn for named company representatives.
Defence Therapeutics (OTCQB: DTCFF) has appointed Dr. Mark Lambermon as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience in pharmaceutical R&D, biotech innovation, and commercial manufacturing, having held key positions at AbbVie Inc. and Baxter Healthcare.
Dr. Lambermon's expertise includes leading global CMC programs, supplier oversight, and implementing GMP-compliant quality systems. He holds a PhD in Cellular Biology from the University of Basel and has completed postdoctoral fellowships at prestigious institutions. As part of his compensation, he was granted 100,000 stock options at $0.80 per share, vesting immediately with a three-year exercise period.
Defence Therapeutics (OTCQB:DTCFF) featured Dr. Amie Phinney, Director of Strategy & Business Advisor, in an interview on Money Talk Radio discussing the company's Accum® drug delivery platform. The interview highlighted how Accum® technology enhances Antibody-Drug Conjugates (ADCs) delivery by improving payload efficiency and reducing toxic side effects.
Dr. Phinney explained that Accum® provides "laser-guided precision" for cancer cell targeting, potentially enabling ADCs to transition from second-line to first-line therapy by addressing dose-limiting toxicity issues. The company's strategy includes worldwide IP protection and plans to partner with existing ADC developers while manufacturing Accum® for various therapeutic applications.
Defence Therapeutics (OTCQB: DTCFF), a biotechnology company focused on drug delivery technologies, has appointed Dr. Amie Phinney, PhD, MBA to its Board of Directors. Dr. Phinney, who recently joined as Strategy and Business Advisor, will now expand her role to help drive governance and long-term value creation.
The company has granted Dr. Phinney 100,000 stock options, exercisable at $0.75 per share for three years, vesting immediately. This appointment strengthens Defence's leadership team as it advances its drug-delivery platform development.
Defence Therapeutics (OTCQB: DTCFF) has successfully completed a non-brokered private placement of debenture units, raising $2 million in gross proceeds. Each unit, priced at $1,000, comprises an 8.0% convertible debenture maturing September 15, 2027, and 1,666 common share purchase warrants.
The debentures are convertible into common shares at $0.60 per share, while warrants are exercisable at $0.75 per share. The company paid $160,000 in finder's fees and issued 266,667 finder's warrants. The proceeds will be used to advance Defence's science programs and for working capital.
FAQ
What is the current stock price of Defence Therapeu (DTCFF)?
What is the market cap of Defence Therapeu (DTCFF)?
